Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 9/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.56 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.56 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.54 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.54 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228187 | 0.88 | VCAM1 (0.64) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL3615295 | 0.87 | VCAM1 (0.59) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL5225915 | 0.85 | VCAM1 (0.64) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL3619380 | 0.85 | SLC25A1 (0.67) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL810667 | 0.83 | MAPT (0.64) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL5225886 | 0.82 | VCAM1 (0.57) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL1250772 | 0.81 | VCAM1 (0.62) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL11752812 | 0.80 | VCAM1 (0.60) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL5227253 | 0.80 | VCAM1 (0.57) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL6677229 | 0.80 | VCAM1 (0.60) | VCAM1DNMT1DNMT3AHSPD1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | VCAM1 3715/4885DNMT1 1743/4885DNMT3A 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.